Literature DB >> 26200403

Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.

Turhan Özler1, Çağatay Uluçay1, Ayberk Önal1, Faik Altıntaş1.   

Abstract

OBJECTIVE: Prevention of deep venous thrombosis (DVT) and associated pulmonary embolism following major orthopedic surgeries is challenging, and there is an increased interest in developing new treatment strategies. We compared 2 switch-therapy modalities-enoxaparin to rivaroxaban and enoxaparin to dabigatran-and enoxaparin monotherapy for preventing DVT after total knee arthroplasty (TKA) and total hip arthroplasty (THA).
METHODS: This was a prospective, non-blinded, randomized controlled study. We selected 180 eligible patients out of 247 patients undergoing TKA or THA. During the preoperative checkup, patients were randomized to receive either enoxaparin (enoxaparin group) or switch-therapy regimens, comprising enoxaparin during hospitalization and rivaroxaban (rivaroxaban group) or dabigatran (dabigatran group) during the outpatient period. All patients were evaluated for DVT using Doppler ultrasonography (USG) 6 weeks postoperatively. The primary efficacy outcome was the prevention of symptomatic or Doppler ultrasonography (USG)-proven DVT, whereas the primary safety outcome was the incidence of bleeding during the DVT-prophylaxis period.
RESULTS: Doppler USG at 6 weeks after surgery revealed no signs of DVT in any patient. During the hospitalization period, only 2 major bleeding events were reported (1 [1.6%] in the enoxaparin group and 1 [1.6%] in the dabigatran group). No major bleeding events were reported during the outpatient follow-up period in any group. Differences among the 3 groups regarding bleeding events were not statistically significant (p>0.05).
CONCLUSION: When using switch-therapy modalities, clinicians can take advantage of the safety of enoxaparin during the hospitalization period and ease of use of new oral anticoagulant drugs during the outpatient period.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26200403     DOI: 10.3944/AOTT.2015.14.0219

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


  8 in total

1.  Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-articular and intravenous tranexamic acid in total knee arthroplasty.

Authors:  Panayiotis K Karampinas; Panayiotis D Megaloikonomos; Kalliopi Lampropoulou-Adamidou; Eleftherios G Papadelis; Andreas F Mavrogenis; John A Vlamis; Spyros G Pneumaticos
Journal:  Eur J Orthop Surg Traumatol       Date:  2018-09-17

2.  Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement.

Authors:  Yi-Min Zhang; Xin Jiang; Yan-Shan Sun
Journal:  Biosci Rep       Date:  2017-06-21       Impact factor: 3.840

3.  Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.

Authors:  Andréa Senay; Milanne Trottier; Josée Delisle; Andreea Banica; Benoit Benoit; G Yves Laflamme; Michel Malo; Hai Nguyen; Pierre Ranger; Julio C Fernandes
Journal:  Vasc Health Risk Manag       Date:  2018-05-08

4.  Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.

Authors:  Jichao Liu; Jinlong Zhao; Yong Yan; Jinping Su
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

5.  Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis.

Authors:  Ya Zhou; Zhihao Yao; Linjie Zhu; Yong Tang; Jie Chen; Jianming Wu
Journal:  Front Pharmacol       Date:  2021-02-02       Impact factor: 5.810

6.  Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis.

Authors:  Zhi Yu; Ping Shan; Xiaoxia Yang; Xin-Jiang Lou
Journal:  Biosci Rep       Date:  2018-11-13       Impact factor: 3.840

Review 7.  Use of oral anticoagulants for the prevention of thromboembolic events in the post-operative period of hip arthroplasty: a systematic review.

Authors:  Anderson Reus Trevisol; Eduardo Felipe Mandarino Coppi; Julia Pancotte; Emanuelly Casal Bortoluzzi; Gabriel Pozzobon Knop
Journal:  Rev Bras Ortop       Date:  2018-07-27

Review 8.  New Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Total Hip and Knee Arthroplasty: A Systematic Review and Network Meta-Analysis.

Authors:  Yi-Hu Yi; Song Gong; Tian-Lun Gong; Ling-Yun Zhou; Can Hu; Wei-Hua Xu
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.